Brand Name | Status | Last Update |
---|---|---|
nexplanon | New Drug Application | 2024-12-13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Contraception | D003267 | — | — | — | 3 | 6 | 4 | 1 | 14 |
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 1 | 2 | 3 |
Uterine hemorrhage | D014592 | — | — | — | 2 | — | 1 | — | 3 |
Metrorrhagia | D008796 | — | N92.1 | — | — | — | 1 | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dysmenorrhea | D004412 | — | N94.6 | — | 1 | 2 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperplasia | D006965 | EFO_0000536 | — | — | 1 | — | — | 1 | 2 |
Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | 2 | 3 |
Pregnancy rate | D018873 | — | — | 1 | — | — | — | — | 1 |
Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hormonal contraception | D000080282 | — | — | — | — | — | — | 2 | 2 |
Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 2 | 2 |
Weight loss | D015431 | — | — | — | — | — | — | 2 | 2 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
Microbiota | D064307 | — | — | — | — | — | — | 1 | 1 |
Pharmacokinetics | D010599 | — | — | — | — | — | — | 1 | 1 |
Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 1 | 1 |
Sexual behavior | D012725 | — | — | — | — | — | — | 1 | 1 |
Sexually transmitted diseases | D012749 | — | A50-A64 | — | — | — | — | 1 | 1 |
Body weight changes | D001836 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Etonogestrel |
INN | etonogestrel |
Description | Etonogestrel is a medication which is used as a means of birth control for women. It is available as an implant placed under the skin of the upper arm under the brand names Nexplanon and Implanon. It is a progestin that is also used in combination with ethinylestradiol, an estrogen, as a vaginal ring under the brand names NuvaRing and Circlet. Etonogestrel is effective as a means of birth control and lasts at least three or four years with some data showing effectiveness for five years. Following removal, fertility quickly returns.
|
Classification | Small molecule |
Drug class | estrogens; progestins |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC |
PDB | — |
CAS-ID | 54048-10-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1531 |
ChEBI ID | 50777 |
PubChem CID | 21729469 |
DrugBank | DB00294 |
UNII ID | 304GTH6RNH (ChemIDplus, GSRS) |